KMDA vs. PRTK, ALT, FULC, MIRM, PRTA, DAWN, ABCL, LQDA, COLL, and TYRA
Should you be buying Kamada stock or one of its competitors? The main competitors of Kamada include Paratek Pharmaceuticals (PRTK), Altimmune (ALT), Fulcrum Therapeutics (FULC), Mirum Pharmaceuticals (MIRM), Prothena (PRTA), Day One Biopharmaceuticals (DAWN), AbCellera Biologics (ABCL), Liquidia (LQDA), Collegium Pharmaceutical (COLL), and Tyra Biosciences (TYRA). These companies are all part of the "medical" sector.
Kamada (NASDAQ:KMDA) and Paratek Pharmaceuticals (NASDAQ:PRTK) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.
Kamada has higher earnings, but lower revenue than Paratek Pharmaceuticals. Paratek Pharmaceuticals is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.
In the previous week, Kamada's average media sentiment score of 0.00 equaled Paratek Pharmaceuticals'average media sentiment score.
Paratek Pharmaceuticals received 123 more outperform votes than Kamada when rated by MarketBeat users. However, 65.13% of users gave Kamada an outperform vote while only 62.30% of users gave Paratek Pharmaceuticals an outperform vote.
Kamada has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, Paratek Pharmaceuticals has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500.
Kamada currently has a consensus price target of $11.00, suggesting a potential upside of 115.69%. Paratek Pharmaceuticals has a consensus price target of $2.15, suggesting a potential downside of 3.59%. Given Kamada's stronger consensus rating and higher probable upside, equities analysts clearly believe Kamada is more favorable than Paratek Pharmaceuticals.
20.4% of Kamada shares are owned by institutional investors. Comparatively, 53.6% of Paratek Pharmaceuticals shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 8.0% of Paratek Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Kamada has a net margin of 8.33% compared to Paratek Pharmaceuticals' net margin of -35.44%. Kamada's return on equity of 5.50% beat Paratek Pharmaceuticals' return on equity.
Summary
Kamada beats Paratek Pharmaceuticals on 12 of the 16 factors compared between the two stocks.
Get Kamada News Delivered to You Automatically
Sign up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
